ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 0444

Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate Versus Biologic DMARDs: A Real-World Analysis

Mahd Khan1, Jacob Boice1, Katherine Gnegy1, Arlie Dolly1, Sushil Pokharel1, Robert McMahon2, Aishwarya Shimpi2, Kelly Tran2, Muqtasid Khan3, Farah Khan4, Sara Rasul4, Ahsan Iqbal5, Erik Escuro2 and Jamie Latos2

Affiliations: 1West Virginia University School of Medicine, Department of Internal Medicine, Morgantown, WV, 2West Virginia University School of Medicine, Department of Medicine, Division of Rheumatology, Morgantown, WV, 3University of Alabama at Birmingham Heersink School of Medicine, Huntsville Internal Medicine Residency Program, Huntsville, AL, 4Khyber Medical College, Peshawar, Pakistan, 5West Virginia University Medicine Thomas Hospitals, Division of Rheumatology, Charleston, WV

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: Biologicals, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

Session Information

Date: Sunday, November 8, 2026

Title: (0440-0470) Rheumatoid Arthritis - Treatment Poster A

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis (RA) is associated with a higher risk of venous thromboembolism (VTE) compared with the general population. The comparative risk of VTE among patients treated with methotrexate versus biologic DMARDs remains incompletely defined. We evaluated the incidence of VTE in RA patients initiating methotrexate compared with biologic DMARDs using a large multicenter database.

Methods: We conducted a retrospective cohort study using the TriNetX Research Network. Rheumatoid arthritis (RA) is classified according to the 2010 ACR/EULAR classification criteria as the presence of clinical synovitis in at least one joint not better explained by another diagnosis, with a cumulative score ≥6/10 from 4 domains: joint involvement, serology, acute-phase reactants, and symptom duration. Adults ≥18 years with RA were identified in the TriNetX database. Patients were categorized into those who initiated methotrexate without prior bDMARD exposure (Cohort 1) or any bDMARD (Cohort 2) on or after January 1, 2015 through April 23, 2026. The index date was defined as the first qualifying prescription. The primary outcome was VTE (deep vein thrombosis or pulmonary embolism), assessed from 1 day post-index through available follow-up. 1:1 propensity score matching was performed on 29 characteristics including demographics (age, sex, race), comorbidities, and laboratory values. Kaplan-Meier survival analysis and Cox proportional hazards models compared VTE incidence between matched cohorts.

Results: Before matching, 115,879 methotrexate and 132,526 bDMARD patients were identified. After propensity score matching, 97,960 patients remained in each cohort. Baseline characteristics were well-balanced (standardized differences < 0.1 for all matched variables).

VTE occurred in 6,189 methotrexate-treated patients (6.3%) versus 6,407 bDMARD-treated patients (6.5%). Methotrexate was associated with a slightly lower risk of VTE (risk ratio 0.97, 95% CI 0.93-0.99) with an absolute risk difference of -0.2% (95% CI -0.4% to -0.0%, P=0.045).

In time-to-event analysis, bDMARD use was associated with a modestly increased hazard of VTE compared with methotrexate (HR 1.05, 95% CI 1.01-1.09; p< 0.01). Kaplan-Meier analysis showed a statistically significant difference between groups (log-rank χ²=6.95, p=0.008).

Conclusion: In this large propensity-matched analysis of RA patients, biologic DMARD therapy was associated with a small but statistically significant increase in VTE risk compared with methotrexate. Although the absolute difference was modest, these findings may suggest a potential association between immunosuppressive strategy and VTE risk, warranting further study.

Supporting image 1Baseline Demographic Characteristics of Patients with Rheumatoid Arthritis Treated with Methotrexate (MTX) vs Biologic DMARDs, Before and After Propensity Score Matching


Disclosures: M. Khan: None; J. Boice: None; K. Gnegy: None; A. Dolly: None; S. Pokharel: None; R. McMahon: None; A. Shimpi: None; K. Tran: None; M. Khan: None; F. Khan: None; S. Rasul: None; A. Iqbal: None; E. Escuro: None; J. Latos: None.

To cite this abstract in AMA style:

Khan M, Boice J, Gnegy K, Dolly A, Pokharel S, McMahon R, Shimpi A, Tran K, Khan M, Khan F, Rasul S, Iqbal A, Escuro E, Latos J. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate Versus Biologic DMARDs: A Real-World Analysis [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/comparative-risk-of-venous-thromboembolism-in-rheumatoid-arthritis-patients-treated-with-methotrexate-versus-biologic-dmards-a-real-world-analysis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-risk-of-venous-thromboembolism-in-rheumatoid-arthritis-patients-treated-with-methotrexate-versus-biologic-dmards-a-real-world-analysis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology